MetroBiotech, Co-Founded by Harvard's David Sinclair, Launches Human Trial of New NAD+ Booster MIB-725

Researchers began a first-in-human trial of MIB-725, a drug designed to raise NAD+, a molecule cells use for energy and repair. The trial enrolled human volunteers to check safety, side effects, and how the body handles the drug. The report announced the trial but did not provide results showing that it improved health or slowed aging. It also did not establish whether raising NAD+ benefits ordinary people.

What this means for you: This announcement is not evidence that MIB-725 works or that NAD+ supplements are useful. There is no reason to buy products based on this trial launch alone.